KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 7.05%.

  • Neogenomics' EBIT Margin rose 36400.0% to 7.05% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.93%, marking a year-over-year decrease of 19900.0%. This contributed to the annual value of 15.93% for FY2025, which is 19900.0% down from last year.
  • According to the latest figures from Q4 2025, Neogenomics' EBIT Margin is 7.05%, which was up 36400.0% from 14.38% recorded in Q3 2025.
  • Neogenomics' EBIT Margin's 5-year high stood at 7.05% during Q4 2025, with a 5-year trough of 44.4% in Q1 2022.
  • For the 5-year period, Neogenomics' EBIT Margin averaged around 20.87%, with its median value being 18.7% (2021).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -374600bps in 2021, then soared by 188400bps in 2023.
  • Over the past 5 years, Neogenomics' EBIT Margin (Quarter) stood at 33.06% in 2021, then soared by 42bps to 19.02% in 2022, then skyrocketed by 37bps to 11.94% in 2023, then grew by 10bps to 10.7% in 2024, then soared by 34bps to 7.05% in 2025.
  • Its EBIT Margin was 7.05% in Q4 2025, compared to 14.38% in Q3 2025 and 26.27% in Q2 2025.